Literature DB >> 15919450

Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy.

T Iwahori1, H Takeuchi, N Matsuno, Y Johjima, O Konno, Y Nakamura, K Hama, M Uchiyama, T Ashizawa, K Okuyama, T Nagao, M Abudoshukur, T Hirano, K Oka.   

Abstract

We performed 24-hour monitoring of cyclosporine (NEO) and tacrolimus (TAC) blood concentrations, evaluating pharmacokinetic parameters and characterizing circadian variations. The monitoring was performed in 10 instances on nine patients administered NEO and 12 out of 11 patients administered TAC. All cases were administered equally divided doses of drugs twice daily orally. Blood samples were taken before and 1, 2, 3, 4, 6, and 12 hours after NEO or TAC administration in the morning and evening. The pharmacokinetic parameters were compared between morning and evening administrations of both drugs. AUC0-12, AUC0-4, C(max), C2, and C(max)/C(min) of NEO and TAC were significantly lower during the evening compared with morning administrations. C(min) values were significantly higher in the evening. T(max) of NEO was longer in evening, although there was not a significant difference; T(max) of TAC was significantly longer in the evening. We found that NEO and TAC administrations in the evening resulted in reduced bioavailability and delayed absorption when compared with drug administrations in the morning. It was thought that the difference in bioavailability between morning and evening administrations was smaller with TAC, because TAC shows lower peak levels and a flatter blood concentration curve than NEO. C(min) was higher after evening administration than morning because of delayed absorption, though the bioavailability of both drugs decreased in the evening. These results suggest that we have to appreciate apparently high trough levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919450     DOI: 10.1016/j.transproceed.2005.02.104

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  9 in total

1.  Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers.

Authors:  Timothy G K Mant; Daniel Bradford; Dipti M Amin; Jaya Pisupati; Yoshikazu Kambayashi; Yoshitaka Yano; Kazushige Tanaka; Takuko Yamada-Sawada
Journal:  Br J Clin Pharmacol       Date:  2006-10-31       Impact factor: 4.335

Review 2.  Chronopharmacokinetics of ciclosporin and tacrolimus.

Authors:  Massimo Baraldo; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Prediction of cyclosporine A blood levels: an application of the adaptive-network-based fuzzy inference system (ANFIS) in assisting drug therapy.

Authors:  Sezer Gören; Adem Karahoca; Filiz Y Onat; M Zafer Gören
Journal:  Eur J Clin Pharmacol       Date:  2008-05-06       Impact factor: 2.953

4.  Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.

Authors:  Shigeru Satoh; Hideaki Kagaya; Mitsuru Saito; Takamitsu Inoue; Masatomo Miura; Kazuyuki Inoue; Kazuyuki Numakura; Norihiko Tsuchiya; Hitoshi Tada; Toshio Suzuki; Tomonori Habuchi
Journal:  Br J Clin Pharmacol       Date:  2008-04-22       Impact factor: 4.335

5.  Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients.

Authors:  Sarah Leyking; Karin Budich; Kai van Bentum; Stephan Thijssen; Hashim Abdul-Khaliq; Danilo Fliser; Martina Sester; Urban Sester
Journal:  J Transl Med       Date:  2015-02-06       Impact factor: 5.531

6.  Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation.

Authors:  Pere Fontova; Helena Colom; Raül Rigo-Bonnin; Lisanne N van Merendonk; Anna Vidal-Alabró; Nuria Montero; Edoardo Melilli; Maria Meneghini; Anna Manonelles; Josep M Cruzado; Juan Torras; Josep Maria Grinyó; Oriol Bestard; Nuria Lloberas
Journal:  Front Pharmacol       Date:  2021-03-17       Impact factor: 5.810

7.  Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.

Authors:  Ahmed Hamed Salem; Denise Koenig; Dawn Carlson
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

8.  Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers.

Authors:  A van Rongen; L Kervezee; Mje Brill; H van Meir; J den Hartigh; H-J Guchelaar; J H Meijer; J Burggraaf; F van Oosterhout
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-07-24

9.  Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients.

Authors:  Marte Theie Gustavsen; Karsten Midtvedt; Ida Robertsen; Jean-Baptiste Woillard; Jean Debord; Rolf Anton Klaasen; Nils Tore Vethe; Stein Bergan; Anders Åsberg
Journal:  Clin Transl Sci       Date:  2020-07-11       Impact factor: 4.689

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.